<DOC>
	<DOCNO>NCT02310568</DOCNO>
	<brief_summary>This study aim evaluate whether PF-06372865 safe effective treatment sub-optimally control symptom generalize anxiety disorder two 4-week treatment period use Sequential Parallel Comparison Design ( SPCD ) . The study use Hamilton Anxiety Rating Scale ( HAM-A ) measure change symptom baseline two dos PF-06372865 compare placebo .</brief_summary>
	<brief_title>POC Study Partially Responsive Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Inclusion criterion : 1 . Outpatient male females 18 65 year age ( inclusive ) . 2 . Diagnostic Statistical Manual Mental Disorders Fourth edition Text Revised ( DSM IV TR ) diagnosis GAD ( DSM IV TR , 300.02 ) , confirm primary diagnosis Mini international neuropsychiatric interview ( MINI ) structure interview . 3 . All subject must total HAM A ( via SIGH A ) score 22 screening . In addition , score baseline visit must also within 20 % score screen . 4 . Subjects must also Covi Anxiety Scale score 9 Raskin Depression Scale score 7 Screening ( Visit 1 ) visit ensure predominance anxiety symptom depression symptom . 5 . Taking FDA approve GAD treatment ( escitalopram 10 20 mg total daily dose , paroxetine 20 50 mg total daily dose , duloxetine 60 120 mg total daily dose , venlafaxine 75 225 mg total daily dose ) stable FDA approve dosage least two consecutive month current episode immediately prior screen visit . Sertraline citalopram also permit background treatment GAD dose 50 200 mg total daily dose 20 40 mg total daily dose , respectively . Exclusion criterion : 1 . Subjects history daily benzodiazepine use within one month screen visit . 2 . Recent ( defined meeting disorder diagnostic criterion last 6 month ) DSM IV TR Axis I diagnosis generalized anxiety disorder , follow exception : . Subjects recent ( last 2 month ) major depressive disorder may enrol anxiety symptom predominant depressive symptom , judge Covi/Raskin criterion list confirm GAD primary diagnosis MINI structure interview . b. Comorbid social phobia and/or specific phobia permit long anxiety symptom due disorder clinically less significant anxiety symptom due GAD GAD confirm primary diagnosis MINI structure interview . 3 . Recent ( defined meeting disorder diagnostic criterion last 6 month ) DSM IV TR Axis I panic disorder without agoraphobia , Post Traumatic Stress Disorder ( PTSD ) , dissociative disorder , obsessive compulsive disorder , attention deficit disorder . If subject past misdiagnosis disorder , subject another psychiatric disorder opinion investigator affect suitability subject study base safety consideration , investigator need contact sponsor prior screen . 4 . Past and/or current DSM IV TR diagnosis schizophrenia , schizoaffective disorder , psychotic disorder , bipolar disorder ( I II ) , factitious disorder cognitive disorder ( include delirium , dementia , amnestic disorder ) . 5 . Presence comorbid personality disorder ( Axis II ) base DSM IV TR . 6 . Subjects meet DSM IV TR define diagnostic criterion psychoactive substance dependence ( exclude nicotine dependence ) within 12 month screen DSM IV TR define substance abuse within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PF 06372865</keyword>
	<keyword>generalize anxiety disorder</keyword>
	<keyword>outpatient</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>suboptimal response</keyword>
</DOC>